News

Bexion Pharmaceuticals Secures Grant to Propel BXQ-350 Research

Bexion Pharmaceuticals Secures Grant to Propel BXQ-350 Research

Bexion Pharmaceuticals Receives Michael J. Fox Foundation Grant

Bexion Pharmaceuticals, Inc., a dedicated clinical-stage biopharmaceutical company, has received a substantial grant to support its innovative research initiatives. This grant, awarded by The Michael J. Fox Foundation for Parkinson's Research, amounts to $1.4 million and will specifically fund the preclinical development of BXQ-350, Bexion's pioneering drug candidate aimed at treating Parkinson's disease.

Understanding BXQ-350

BXQ-350 is a unique biologic therapy that includes Saposin C, a multifunctional sphingolipid activator protein, which works in synergy with a phospholipid. This cutting-edge approach has shown promise in various Phase 1 trials, demonstrating not only a robust safety profile but also effectively targeting multiple types of solid tumors.

Competitive Edge in Treatment

Bexion’s research has highlighted BXQ-350 as an allosteric activator of glucocerebrosidase (GCase), an enzyme linked to genetic risk factors in Parkinson's disease. This is particularly significant as mutations in the GBA gene, responsible for producing GCase, pose the largest genetic risk for developing Parkinson's, affecting between 5% to 15% of patients. With this understanding, the potential impact of BXQ-350 is immense in providing new treatment options.

Jim Beach, the Chief Executive Officer of Bexion Pharmaceuticals, expressed gratitude for the grant and emphasized the company's commitment to exploring BXQ-350’s potential for neurodegenerative diseases. This initiative aligns with Bexion's mission to provide viable therapeutic avenues for patients who are currently underserved by existing solutions.

Collaborating for Change

Jessica Tome Garcia, PhD, from The Michael J. Fox Foundation, reaffirmed the foundation’s ongoing mission to fund innovative research that could revolutionize treatment methodology for Parkinson's disease. With BXQ-350 representing significant progress in fulfilling the urgent needs of patients, the collaboration between Bexion and MJFF highlights the importance of innovative approaches in biopharmaceutical research.

Current Research and Development Focus

Bexion is not just focused on the preclinical stages of BXQ-350. The company is currently conducting an open-label phase 1b/2 trial, where BXQ-350 is evaluated in combination with standard care for newly diagnosed metastatic colorectal cancer patients. Preliminary data has shown the drug's efficacy across various solid tumor types, and there’s also potential to treat chemotherapy-induced peripheral neuropathy (CIPN), particularly in patients who have undergone treatment involving oxaliplatin.

A Commitment to Advancing Therapy

Bexion Pharmaceuticals holds a promising position in the biopharmaceutical landscape, as the company continues to explore new territories in drug development. With plans to extend beyond solid tumors and delve into broader neuropathic pain therapies, Bexion is determined to address significant unmet medical needs. They have established a positive track record in developing potential treatments for diverse oncological conditions, including pediatric brain tumors and high-grade gliomas.

Investor Relations and Media Contact Information

For investors or media inquiries, Bexion Pharmaceuticals has provided contact details for further information. William Windham of Solebury Strategic Communications is available for investor communications, while Joyce LaViscount represents media inquiries for the company. Their aim is to ensure that interested parties remain informed about Bexion’s advancements and strategic initiatives.

Frequently Asked Questions

What is BXQ-350?

BXQ-350 is Bexion Pharmaceuticals' investigational biologic therapy aimed at treating solid tumors and chemotherapy-induced peripheral neuropathy.

How much funding did Bexion receive?

Bexion Pharmaceuticals was awarded a grant of $1.4 million from The Michael J. Fox Foundation to advance its research in BXQ-350.

Why is the GCase enzyme significant?

The GCase enzyme's significance lies in its link to genetic risk factors for Parkinson's disease, affecting a notable percent of the patient population.

What tumors is BXQ-350 being tested on?

BXQ-350 is currently being tested on various solid tumor types through ongoing clinical trials.

Who can I contact for more information about Bexion?

You can contact William Windham for investor inquiries and Joyce LaViscount for media inquiries at Bexion Pharmaceuticals.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

DigiKey’s Arduino Webinar Puts Edge AI Hardware to Work

Updated Category News Views 34

A Small Board With a Big Practical Question Edge AI is finally getting dragged out of the slide deck and onto the workbench, which is where it ought to prove itself. DigiKey plans to host a free 60-minute webinar on Dec. 2, 2026, at 10 a.m. CST covering Arduino’s new VENTUNO Q edge AI computer. The session promises a hardware tour, an Arduino App Lab walkthrough, and a...

Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!

Updated Category News Views 31

Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 67

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 47

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 46

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 0

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market

Updated Category News Views 32

A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 311

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny

Updated Category News Views 131

Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 106

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading

Top 5 Most Recently Viewed Articles

Big Lots Adjusts Strategy Amid Bankruptcy Process Challenges

Updated Category News Views 183

Big Lots Updates on Court-Supervised Process No Longer Anticipates Closing Previously Announced Sale to Nexus Capital Management Continues Efforts Towards a Going Concern Transaction Gearing Up for Going Out of Business Sales at Remaining Locations Big Lots, Inc. has recently made crucial updates regarding its financial restructuring efforts. The company has announced...

Continue Reading
Detailed Overview of Man Group PLC's Stake in American Axle

Updated Category News Views 133

Key Information About Man Group PLC's Disclosures FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE This document represents a disclosure by a person with interests in relevant securities, specifically when owning 1% or more of American Axle & Manufacturing Holdings, Inc. As per Rule 8.3 of the Takeover Code, certain details regarding the interests and...

Continue Reading
Westlake Chemical Gets Boost from Analysts with New Targets

Updated Category News Views 67

Westlake Chemical Upgraded to Neutral Recently, BofA Securities made a notable adjustment regarding Westlake Chemical (NASDAQ: WLK), changing the stock's rating from Underperform to Neutral. This upgrade included raising the price target to $159 from $151, reflecting a more balanced view on the company's trajectory. The changes stem from a reassessment that weighs current...

Continue Reading
Envision Energy Recognized Among Leading Climate Tech Innovators

Updated Category News Views 209

Envision Energy's Recognition in Climate Technology Envision Energy has earned a well-deserved place on a prestigious list recognizing transformative companies in climate technology. This acknowledgment highlights their significant contributions in the fight against climate change through innovative renewable energy solutions. A Global Leader in Renewable Energy Known for...

Continue Reading
Exploring Franco-Nevada's Ten-Year Investment Journey

Updated Category News Views 155

Understanding Franco-Nevada's Investment Growth Franco-Nevada (NYSE: FNV) has showcased impressive performance over the last decade, delivering an average annual return of 14.64%. With a market capitalization of $30.52 billion, it has consistently outperformed the overall market by 3.21% on an annualized basis. The Impact of Compounding Returns Let's say an investor...

Continue Reading